Connect with us


For Seniors with IBD, Think Safety with Treatments – MedPage Today

Hospitalizations risks were lower with vedolizumab than TNF inhibitors



post featured image

Among older adults with inflammatory bowel disease (IBD), vedolizumab (Entyvio) appeared to be safer than tumor necrosis factor (TNF) inhibitors, a large retrospective study suggested.
After weighting using standardized mean differences, new users of vedolizumab had a lower likelihood of all-cause hospitalization during the 12 months after initiating biologic treatment compared with those starting TNF inhibitors, with a hazard ratio of 0.81 (95% CI 0.68-0.96), according to Bharati Kochar, MD, of…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
Race and ethnicity of some U.S. counties may have key impact on cardiovascular death – News-Medical.Net
Article feature image
Methods for the detection and identification of SARS-CoV-2 variants – EU News